Citadel Advisors
CADL icon

Citadel Advisors’s Candel Therapeutics CADL Stock Holding History

Citadel Advisors’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$454K Sell
44,100
-10,000
-18% -$75.5K ﹤0.01% 10097
2026
Q1 		$265K Sell
54,100
-55,900
-51% -$304K ﹤0.01% 10761
2025
Q4 		$622K Sell
110,000
-13,900
-11% -$74.8K ﹤0.01% 8505
2025
Q3 		$632K Sell
123,900
-182,100
-60% -$1.05M ﹤0.01% 8565
2025
Q2 		$1.55M Buy
306,000
+35,500
+13% +$183K ﹤0.01% 6196
2025
Q1 		$1.53M Sell
270,500
-11,600
-4% -$94.8K ﹤0.01% 6065
2024
Q4 		$2.45M Buy
282,100
+197,100
+232% +$1.16M ﹤0.01% 5217
2024
Q3 		$589K Buy
85,000
+24,800
+41% +$154K ﹤0.01% 7918
2024
Q2 		$373K Buy
+60,200
New +$452K ﹤0.01% 8662

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors's CADL Position: Q2 2026 in Review

Citadel Advisors increased its Candel Therapeutics (CADL) stake by 101% in Q2 2026, buying an estimated $554K and bringing the position to 146,016 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #7206.

Citadel Advisors first reported a position in CADL in Q3 2022 and has held it in 11 quarters since. The position peaked at $2.53M in Q4 2024. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Citadel Advisors held 146,016 shares of Candel Therapeutics worth $1.5M as of Q2 2026.
  • Citadel Advisors bought 73,350 Candel Therapeutics shares in Q2 2026, an estimated $554K.
  • Candel Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #7206 holding.
  • Citadel Advisors first reported a position in Candel Therapeutics in Q3 2022 and has held it in 11 quarters since.
  • Citadel Advisors's Candel Therapeutics position peaked at $2.53M in Q4 2024.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.